Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Astellas Settles with MSN to License Myrbetriq, Securing Royalties and Strategic Focus

Astellas Pharma’s settlement with MSN allows a generic Myrbetriq launch while securing steady royalties, boosting cash flow and supporting its regenerative‑medicine focus.

Dr. Michael Chen

30/04/2026, 08:18

4 minutes to read

Otsuka Holdings: Q1 Earnings Rise, ADC Breakthrough & Bone Health Expansion

Otsuka Holdings’ Q1 earnings grow, while Taiho’s ARC‑02 ADC moves to Phase‑1 and Pharmavite leads bone‑health supplements—showing a balanced, growth‑oriented strategy across pharma and nutraceuticals.

Dr. Michael Chen

29/04/2026, 00:51

4 minutes to read

Unilever’s Wellness Pivot: Boosting Margins, Science, and Global Health

Unilever’s pivot to wellness‑centric consumer health, backed by science‑based nutraceuticals, boosts margins and meets rising health‑conscious demand.

Dr. Michael Chen

27/04/2026, 20:30

4 minutes to read

Regeneron Accelerates Biologic Pipeline With Advanced Manufacturing & AI‑Driven Research

Regeneron’s next‑generation biologics strategy blends advanced protein engineering, AI‑driven discovery, and scalable manufacturing—fueling growth in oncology, immunology, and its core eye‑care hits.

Dr. Michael Chen

27/04/2026, 19:40

4 minutes to read

Regeneron Secures FDA Accelerated Approval for Gene‑Therapy Treating Congenital Hearing Loss

Regeneron’s gene‑therapy REG‑HL1 earns FDA accelerated approval, offering free treatment for rare congenital hearing loss and setting a new standard for equitable, outcome‑based pricing in gene‑therapy development.

Dr. Michael Chen

27/04/2026, 03:00

5 minutes to read

Thermo Fisher’s Q1 2026 Earnings Beat Expectations, Driving Innovation in Life‑Sciences

Thermo Fisher Scientific reports Q1 2026 earnings: $3.15 EPS, 2% revenue rise, and 10% net profit increase, driven by high‑margin life‑science tools and expanding drug‑development partnerships.

Dr. Michael Chen

26/04/2026, 23:21

5 minutes to read

AbbVie’s $1.4 B U.S. Biopharma Campus Uses AI to Boost Manufacturing & Outpace Competition

AbbVie’s $1.4 billion Research Triangle Park campus, set to launch in 2028, blends AI‑driven biomanufacturing and advanced cell‑based platforms to boost U.S. biologic production and secure a leadership edge in immunology and oncology.

Dr. Michael Chen

25/04/2026, 05:42

5 minutes to read

Strong Q1 2026 Results: Sartorius AG Drives Growth in Bioprocess Solutions & Lab Products

Discover how Sartorius AG’s 2026 Q1 growth in Bioprocess Solutions and Lab Products drives stronger margins, regulatory‑ready consumables, and investor confidence.

Dr. Michael Chen

24/04/2026, 04:09

4 minutes to read

Merck KGaA Eyes INBRX‑106 Partnership to Boost Keytruda’s Effectiveness in NSCLC

Merck KGaA eyes a partnership with Inhibrx Biosciences’ NF‑κB modulator INBRX‑106, aiming to boost Keytruda response rates and expand its oncology portfolio through 3D‑culture‑driven preclinical acceleration.

Dr. Michael Chen

24/04/2026, 01:20

3 minutes to read

Johnson & Johnson Q1 2026 Report: Stable Growth, ESG Boost & FDA‑Approved ETHICON 4000 Stapler

Johnson & Johnson’s latest Q1 filing shows steady growth and new sustainability partnership with SPIE, while the FDA’s approval of the ETHICON 4000 surgical stapler highlights cutting‑edge innovation and lower complication rates.

Dr. Michael Chen

23/04/2026, 23:01

5 minutes to read

Newer articles